Predictive Patterns Builds on Molecular Mining
Predictive Patterns, a new Kingston, Ontario-based company founded by Tom Radcliffe and Mark Chatterley of defunct Molecular Mining, announced last week that the company has licensed Molecular Mining’s GeneLinker line of software from Parteq Innovations, the technology-transfer agent for Queen’s University of Kingston.
The company will sell the GeneLinker gene- expression, and proteomics analysis software through the Internet.
Predictive Patterns also announced the release of GeneLinker Gold, version 3.1, and GeneLinker Platinum, version 2.1. Both include the capacity for: exporting SVG and PDF-format graphics; merging based on variables; automatic default visualizations; Kruskal-Wallis statistics to allow for non-parametric independent group comparisons on replicates or classified samples; support for Oracle 9i as a data repository; and the ability to export PCA loadings that describe correlations between components and variables.
Expression Analysis Inks $1.5M EPA Contract
Expression Analysis, a Durham, NC, Affymetrix-platform microarray services provider has entered into a $1.5 million contract to conduct gene-expression analysis for the Environmental Protection Agency, according to a report in the Triangle Business Journal.
Nanostream Raises $22 Million
Nanostream, a Pasadena, Calif.-based developer of lab-on-a-chip microfluidics technology, has held a $22 million first close on its ongoing Series C funding round.
The foue-year-old company has raised some $33 million and hopes to raise an additional $3 million in this round.
Schroder Ventures Prepares to Invest $402M Life Sciences Fund
Schroder Ventures Life Sciences of New York has held a $402 million final close on its third international life sciences fund. The close included 18 new investors, with half of the total commitments coming from North America and the rest from UK and other European investors. The new fund will target investments between $5 million and $20 million into companies in the life sciences sector.
Lark Technologies Retains Investment Banker
Houston-based Lark Technologies said last week that it has retained investment banker Southwest Securities to assist in M&A activities.
The company offers genomic services such as genomic data management and microarray support to the pharmaceutical, diagnostic and agricultural product research and development industries. Lark reported revenues of $2,117,099 in the first quarter of 2003, ending March 31, and net income of $436,738.
Lynx, ISB and IBM Sign Agreement to Study Immune Cell Gene Expression
The Institute for Systems Biology has signed an agreement with Lynx Therapeutics and IBM to study response to infectious diseases in immune cells, the companies announced last week.
Under the agreement, Lynx will use its Massively Parallel Signature Sequencing, or MPSS, technology to profile gene expression in macrophages, in studying the cells’ inflammatory response to microbial infection.
IBM will provide the middleware for the data management and analysis, including licenses to the DB2 Universal Database, the WebSphere studio, and IBM’s middleware tools and algorithms, which Lynx will incorporate into its IT platform, and will include in future sales of instruments.
IBM Research’s computational biology center worked with Lynx and ISB on experimental design, and also will help with analysis of the data. IBM hopes to learn from the project what IT is required for computational systems biology research, the companies said.
The companies did not disclose the financial terms of the agreement.
This is the second collaboration between Lynx and ISB. Lynx is also using MPSS to study gene expression in prostate cancer for ISB, under an agreement begun in May 2002 and renewed for another year May 14.
Caliper Announces Plans to Acquire Zymark
Caliper Technologies said this week it plans to aquire privately held Zymark from its parent, the Berwind company, for $57 million cash and 3.15 million shares of Caliper stock.
Caliper said that Zymark’s lab automation product line and sales force would provide a broader commercial outlet for its own microfluidic LabChip platform.